Recombinant PCSK9 (Evolocumab Biosimilar) 抗体
Our Local Distributor
北京 101111
Quick Overview for Recombinant PCSK9 (Evolocumab Biosimilar) 抗体 (ABIN7795143)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
-
-
Expression System
- Mammalian cells
-
原理
- Evolocumab Biosimilar, Human PCSK9 Monoclonal Antibody
-
产品特性
- What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60 % . The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human PCSK9
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- PCSK9 (Evolocumab Biosimilar)
-
别名
- Evolocumab Biosimilar
-
物质类
- Biosimilar
抗原
-